Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Byer

Otolaryngology Derry, NH Medical Doctor

NPI 1184618803 CMS profile 280099

14A Tsienneto Road, Suite 200, Derry, NH 03038

Open in the dashboard

General payments

$660

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Byer of Derry, NH is reported in the CMS Open Payments database as having received $660 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2023 General $107 3
2022 General $94 4
2021 General $177 3
2020 General $58 3
2019 General $200 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Byer
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Jeffrey Byer were reported at $24. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Jeffrey Byer Otolaryngology median Middle half National median
2019 $200 $194 $82–$512 $163
2020 $58 $118 $42–$280 $114
2021 $177 $167 $63–$444 $132
2022 $94 $216 $84–$545 $149
2023 $107 $235 $93–$588 $160
2024 $0 $280 $111–$699 $164
2025 $24 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $139 1 payment
  2. Intersect ENT, Inc. $127 2 payments
  3. Medtronic, Inc. $120 3 payments
  4. Genzyme Corporation $87 4 payments
  5. GlaxoSmithKline, LLC. $74 2 payments
  6. ALK-Abello, Inc $34 2 payments
  7. Aerin Medical Inc. $29 2 payments
  8. Regeneron Healthcare Solutions, Inc. $27 1 payment
  9. BeiGene USA, Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $490 14 payments
  2. Consulting Fee $170 4 payments
Products named General payments · program years 2019–2025
  1. ENTELLUS - XPRESS ENT DILATION SYSTEM $139 1 payment
  2. SPIROX - LATERA $139 1 payment
  3. ENTELLUS - CYCLONE SINONASAL SUCTION/IRRIGATION SYSTEM $139 1 payment
  4. SINUVA $127 2 payments
  5. NUCALA $74 2 payments
  6. STRAIGHTSHOT $50 1 payment
  7. DUPIXENT Immunology $45 2 payments
  8. DUPIXENT Immunology $43 2 payments
  9. STEALTHSTATION S8 PLATFORM $35 1 payment
  10. MEROCEL $35 1 payment
  11. Other $116 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

724

Median for Otolaryngology: 297

Drug cost

$14,043

Median for Otolaryngology: $6,314

Branded share of claims

4.1%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluocinolone Acetonide Oil Generic 126 $4,605
Ipratropium Bromide Generic 133 $3,006
Montelukast Sodium Generic 294 $2,235
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 17 $1,395
Ofloxacin Generic 30 $1,325
Triamcinolone Acetonide Generic 19 $482
Fluconazole Generic 15 $272
Fluticasone Propionate Generic 20 $268
Cefuroxime Cefuroxime Axetil Brand 13 $182
Methylprednisolone Generic 26 $169

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$67,553

Medicare's payments for the services billed

Medicare patients

570

Average age 76

Services billed

1,916

312 women, 258 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 49%
Ischemic heart disease 24%
Diabetes 23%
Chronic kidney disease 21%
Osteoporosis 18%
Atrial fibrillation 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record